Skip to content

The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders

Effectiveness and Cost-effectiveness of a Digital Stepped-care Mindfulness Intervention for Recovery From Emotional Disorders: a Multicentre Pragmatic Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07458100
Enrollment
464
Registered
2026-03-09
Start date
2026-03-23
Completion date
2028-05-01
Last updated
2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders, Depressive Disorder, Eating Disorders, Emotional Disorders, Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, PTSD

Keywords

Cost-effectiveness, Mindfulness, Recovery, randomized controlled trial, stepped-care, Emotional Disorders

Brief summary

The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are: * Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years? * Is this combined approach more cost-effective than usual care alone? Researchers will compare the group receiving the digital mindfulness intervention plus their usual treatment to the group receiving only their usual treatment to see if the intervention leads to better long-term recovery and represents good value for money. Participants in the intervention group will: * Attend eight weekly 2-hour online group mindfulness sessions. * Use a WeChat mini-program for 49 days of guided mindfulness exercises and daily tasks. * Patients who have not achieved reliable recovery after group retraining voluntarily participate in individual UP&MIED counseling. * Complete regular questionnaires and interviews over two years to track their progress. All participants will continue to receive their usual medical care from their doctors throughout the study.

Detailed description

The prevalence of emotional disorders remains high, with depression and anxiety disorders being the most common (Freeman, 2022; Huang et al., 2019). Although existing treatments can alleviate symptoms in the short term, emotional disorders often follow a chronic and recurrent course, making long-term recovery difficult for patients (Mulder, 2015) and resulting in a persistent and heavy socioeconomic burden (Amos et al., 2018; GBD, 2022). Furthermore, individuals with emotional disorders often exhibit significant diagnostic instability and high comorbidity rates, making single-diagnosis interventions inadequate for real-world treatment needs (Bullis et al., 2019). Consequently, developing intervention strategies applicable to high comorbidity and capable of delivering long-term recovery benefits represents an urgent requirement in current emotional disorder treatment. Transdiagnostic interventions are considered a key approach to meeting this need (Barlow et al., 2020). Grounded in the shared etiology and common mechanisms underlying psychopathology, these interventions enable practitioners to address diverse disorders using a single set of methods. Previous meta-analyses indicate that transdiagnostic interventions, exemplified by Mindfulness-Based Interventions (MBIs), yield moderate improvements in depressive and anxiety symptoms (Cuijpers et al., 2023). Specifically, Mindfulness-Based Stress Reduction (MBSR) has demonstrated potential as an alternative to medication in treating anxiety disorders (Hoge et al., 2023). For preventing depressive relapse in recurrent depression patients, Mindfulness-Based Cognitive Therapy (MBCT) proved as effective as maintenance antidepressant medication (Kuyken et al., 2015). The "Mindfulness Intervention for Emotional Distress" (MIED) employed in this study is a transdiagnostic psychological intervention developed based on MBSR and the "Unified Protocol for Cross-Diagnostic Treatment of Emotional Disorders" (UP). This program proposes a transdiagnostic psychopathology diamond model for emotional disorders, identifying four core pathological mechanisms hindering recovery: low distress tolerance, cognitive inflexibility, excessive emotional behavior, and abnormal engaging in life (Liu, 2024). MIED targets these four mechanisms through mindfulness practices combined with intervention strategies from UP (e.g., cognitive reappraisal, interoceptive exposure). This improvement of underlying pathological mechanisms is considered crucial for facilitating patients' transition from short-term symptom relief to robust, long-term recovery. At the same time, the application of digital technology and group formats in psychological interventions continues to expand, providing low-threshold, scalable pathways for integrating transdiagnostic mindfulness interventions into routine healthcare systems (Schaeuffele et al., 2024). The digital MIED program has demonstrated promising effects in improving emotional distress and accelerating symptom improvement in emotional disorders across preliminary short-term studies (Ju et al., 2022; Li et al., 2024; Li et al., 2025; Wang et al., 2024). The high-frequency interaction compensates for the lack of proactive intervention tools in current clinical care. However, the efficacy of transdiagnostic interventions in promoting long-term recovery remains under-validated. Most transdiagnostic interventions, including mindfulness-based approaches, have primarily focused on single diagnostic dimensions (Barlow et al., 2017) or non-clinical samples (Lindegaard et al., 2021) , and generally lack large-sample support and long-term follow-up (Cuijpers et al., 2023; Newby et al., 2015; Schaeuffele et al., 2024) , making it difficult to reflect the long-term benefits for individuals with emotional disorders within real-world clinical pathways. Furthermore, the potential cost-effectiveness of such interventions remains under-examined (Schaeuffele et al., 2024). Against the backdrop of prolonged course and high comorbidity in emotional disorders, these evidence gaps constrain the effective integration of cross-diagnostic mindfulness interventions within routine healthcare systems. Beyond this, the current limited understanding of the mechanisms of action also constrains improvements in treatment outcomes (Kazdin, 2007). While numerous theories have proposed hypotheses regarding these mechanisms (Baer, 2003; Brown et al., 2007; Garland et al., 2015; Liu, 2024; Shapiro et al., 2006), research on the mechanisms underlying MBIs remains lacking in systematic validation when measured against the criteria for establishing psychological intervention mechanisms proposed by Kazdin (Kazdin, 2007, 2009). No variables have been found to satisfy most mechanism validity criteria, with particularly insufficient evidence meeting experimental manipulation, temporal priority, and consistency criteria. More rigorous, high-quality research is needed to examine MBI mechanisms. To address these evidence gaps, we plan to conduct a large-scale, multicenter, pragmatic randomized controlled trial evaluating the long-term efficacy and cost-effectiveness of a transdiagnostic digital mindfulness intervention as an adjunct to treatment as usual (TAU). This study will also incorporate an examination of MBI mechanisms of action, aiming to facilitate further optimization of intervention protocols.

Interventions

MIED is a psychological intervention program based on "Mindfulness-Based Stress Reduction" (MBSR) and the "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP), proposed by one of our authors. It includes a psychological diamond model of emotional distress and core intervention strategies (Liu, 2024). This program, in the form of mental health education courses, is suitable for patients with emotional disorders such as anxiety and depression. It has shown good effects in alleviating emotional distress in a series of preliminary studies (Ju et al., 2022; Li et al., 2023; Li et al., 2025; Wang et al., 2024). In this study, the intervention mainly adopts a step-care model, dynamically adjusting the intensity of the intervention according to the patient's recovery progress. All intervention content revolves around the four core transdiagnostic mechanisms of the MIED psychological diamond model and their corresponding core intervention strategies.

Sponsors

Peking University
Lead SponsorOTHER
WU'AN FIRST PEOPLE'S HOSPITAL
CollaboratorUNKNOWN
Xi'an Mental Health Center
CollaboratorUNKNOWN
The Second Hospital of Anhui Medical University
CollaboratorOTHER
The Guangxi Zhuang Autonomous Region Brain Hospital
CollaboratorUNKNOWN
DONG GUAN SEVENTH PEOPLE'S HOSPITAL
CollaboratorUNKNOWN
Affiliated Mental Health Center of Kunming Medical University
CollaboratorUNKNOWN
People's Hospital of Zhengzhou University
CollaboratorOTHER
The Affiliated Brain Hospital of Guangzhou Medical University
CollaboratorUNKNOWN
THE SIXTH AFFILIATED HOSPITAL OF GUANGDONG PHARMACEUTICAL UNIVERSITY
CollaboratorUNKNOWN
Xiamen Medical College Affiliated Xian Yue Hospital
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Data analysts (as part of the investigator team) are masked during the primary analysis phase, working with group codes (e.g., A/B) and unblinding only after completion of the main analysis to minimize bias .

Intervention model description

This study follows a 3-step sequential stepped care model supported by a continuous AI-assisted Q&A service available throughout the study period. Step 1 (Weeks 1-8) involves an 8-week online group Mindfulness-Informed Emotional Distress (MIED) course (2h/weekly) led by certified instructors and a 49-day self-guided digital practice via a WeChat mini-program, followed by psychiatric medication management education; Step 2 (Months 1-6 post-intervention) is a maintenance phase providing three optional group booster sessions (1-2h) at months 1, 3, and 6 to consolidate mindfulness gains; Step 3 (Months 6-8 post-intervention) offers intensified individual UP & MIED counseling (up to eight 50-minute sessions) for participants not achieving reliable recovery, focusing on personalized strategy integration and functional rehabilitation.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Age: 18-65 years. 2. Diagnosed with an emotional disorder by a outpatient psychiatrist, including depressive disorders, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder), obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders (e.g., anorexia nervosa, bulimia nervosa). 3. Symptom severity meeting the threshold: PHQ-9 score ≥10 or GAD-7 score ≥8.

Exclusion criteria

1. Current diagnosis of psychotic disorders or bipolar disorder. 2. Current organic mental disorders, pervasive developmental disorders, severe cognitive impairment, or substance use disorders. 3. Current suicide risk (PHQ-9 item 9 score \>2). 4. Antisocial personality disorder. 5. Severe medical illnesses that may affect intervention participation or require recent hospitalization. 6. Previous participation in a systematic 8-week mindfulness course. 7. Inability to access the internet.

Design outcomes

Primary

MeasureTime frameDescription
Time to Reliable Recoveryat baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionAccording to the standard definition of the IAPT (Improving Access to Psychological Therapies) system (El Baou et al., 2023; Gyani et al., 2013), reliable recovery requires meeting both of the following conditions simultaneously: (1) Reliable improvement: a decrease in PHQ-9 score of ≥6 points, or a decrease in GAD-7 score of ≥4 points, compared to baseline; (2) Symptoms below clinical thresholds: PHQ-9 \< 10 and GAD-7 \< 8. Time to reliable recovery is defined as the time from randomization to the first point at which both of the above criteria are met.

Secondary

MeasureTime frameDescription
Time to relapseat baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionTime to relapse is defined as the time from achieving reliable recovery to the point at which, at any follow-up assessment, either of the following criteria is met: a PHQ-9 score ≥ 10 or a GAD-7 score ≥ 8
Rate of reliable improvementat baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionReliable improvement is a decrease in PHQ-9 score of ≥6 points, or a decrease in GAD-7 score of ≥4 points, compared to baseline. The rate of reliable improvement was calculated at each assessment time point.
Rate of reliable recoveryat baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionReliable recovery requires meeting both of the following conditions simultaneously: (1) Reliable improvement (2) Symptoms below clinical thresholds: PHQ-9 \< 10 and GAD-7 \< 8. The rate of reliable recovery was calculated at each assessment time point.
Deterioration rateat baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionDeterioration is defined according to IAPT criteria as a clinically significant worsening from baseline, operationalized as: PHQ-9 increase ≥ 6 points, or GAD-7 increase ≥ 4 points. The rate of deterioration was calculated at each assessment time point.
Health related quality of lifeat baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionUsing the EQ-5D-5L to measure, obtain health utility index and its changes over time, for estimating quality-adjusted life years (QALYs).The EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) is a standardized measure of health-related quality of life. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale ranging from 1 (no problems) to 5 (extreme problems), describing the respondent's health status on the day of assessment. In addition, the EQ-5D-5L includes a visual analogue scale (EQ-VAS), on which participants rate their overall health from 0 (the worst health you can imagine) to 100 (the best health you can imagine)
Cost-effectivenessat baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionThe Treatment Inventory of Costs in Patients with Psychiatric Disorders (TIC-P) is designed to systematically assess both the direct medical costs (e.g., outpatient visits, hospitalizations, medication expenses) and indirect productivity losses (e.g., absenteeism, reduced work efficiency) associated with psychiatric disorders in adults. It includes a combination of quantitative and qualitative items and collects data through self-report by patients to evaluate the economic burden related to mental illness. Structured with a multidimensional framework, the TIC-P covers the frequency of healthcare resource utilization, cost accounting, and the impact on social functioning, enabling a comprehensive estimation of the economic costs associated with mental health interventions. The "cost" part of cost-effectiveness is measures with TIC-P, whereas the "effectiveness" part is the 24 months rate of reliable recovery.
Cost-utilityat baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionCost is measured with TIC-P ; utility - QALYs derived from the EQ-5D-5L conversion.
Severity of depressive symptomsat baseline(T0), at week3(T1), at week5(T2), at post-intervention(T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention.Depressive symptoms measured using PHQ-9, focusing on how depression change over time.
Severity of anxiety symptomsat baseline (T0), at week 3 (T1), at week 5 (T2), at post-intervention (T3), and at 6 (T4), 12 (T5), 18 (T6), and 24 (T7) months after the intervention.Anxiety symptoms measured using GAD-7, focusing on how anxiety symptoms change over time.
Severity of insomnia symptomsat baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the interventionInsomnia symptoms measured using ISI, focusing on how insomnia symptoms change over time.
Severity of somatic symptomsat baseline (T0), at week 3 (T1), at week 5 (T2), at post-intervention (T3), and at 6 (T4), 12 (T5), 18 (T6), and 24 (T7) months after the intervention.Somatic symptoms measured using SSS-8, focusing on how somatic symptoms change over time.

Countries

China

Contacts

CONTACTDongyang Chen
psychen@stu.pku.edu.cn+8618810673387
CONTACTElena Gomzyakova
lenagom@stu.pku.edu.cn+8618665380155
PRINCIPAL_INVESTIGATORXinghua Liu

School of Psychological and Cognitive Sciences,Peking University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026